Individual Final Project

SECTION 1: ABSTRACT

Seasonal allergic rhinitis affects hundreds of millions of people globally, heavily driven by major pollen allergens like Bet v 1 from birch trees. Current treatments rely on systemic pharmaceuticals, such as antihistamines or steroids, that manage human immune symptoms post-exposure but fail to address the environmental trigger itself. This project addresses this critical gap by shifting the paradigm from symptom management to active, localized bioremediation inside the human nasal cavity. The broad objective of this project is to engineer a “Living Bio-Shield”: a bacterial genetic circuit designed to operate within a nasal commensal that detects and neutralizes pollen proteins upon inhalation. We hypothesize that a chimeric two-component receptor system can be engineered to specifically bind Bet v 1, subsequently triggering a genetic circuit to secrete neutralizing nanobodies (VHH domains) via a Sec-dependent pathway. The specific aims involve designing the chimeric receptor in silico, assembling the genetic circuit plasmid, and validating the computational folding and binding affinity of the receptor-nanobody complex. This will be achieved using bioinformatics databases, AlphaFold for protein design, Benchling for DNA construct assembly, and simulated structural analysis. By neutralizing allergens before they interact with the mucosal epithelium, this project establishes a novel preventative biotherapeutic platform for respiratory health.

SECTION 2: PROJECT AIMS

Aim 1: Experimental Aim (this project): The first aim of my final project is to design and computationally validate a chimeric Two-Component System (TCS) receptor and its associated genetic circuit by utilizing Benchling for DNA construct design and AlphaFold-Multimer for protein structure prediction. This aim focuses on the in silico fusion of a known Bet v 1 nanobody (such as Nb16) to the periplasmic domain of an EnvZ receptor, mapping the resulting operon alongside a Sec-tagged nanobody secretion gene.

Aim 2: Development Aim: The next step following a successful in silico design in Aim 1 would be to physically synthesize the genetic construct using Twist Biosciences, transform it into a lab-safe test chassis (like Bacillus subtilis or E. coli), and validate the active secretion and neutralization of Bet v 1 using in vitro ELISA and SDS-PAGE assays.

Aim 3: Visionary Aim: The long-term vision for this project is to deploy this genetic circuit into a human nasal commensal (such as Staphylococcus epidermidis) to create a commercially viable “Probiotic Nasal Spray” that establishes a persistent, localized defense against airborne allergens. This challenges the existing clinical paradigm of reactive immunotherapy, enabling a proactive capability to continuously filter and neutralize environmental toxins or viruses directly at the point of respiratory entry.

SECTION 3: BACKGROUND

Background and Literature Context The current state of allergy mitigation heavily relies on either avoidance or post-exposure immune suppression, leaving a significant gap in technologies that neutralize allergens at the environmental-mucosal interface. Recent advancements in protein engineering have successfully identified high-affinity camelid nanobodies (VHH) that bind specifically to Bet v 1, effectively blocking human IgE recognition (Levin et al., Journal of Immunology, 2014). Concurrently, synthetic biology has demonstrated the feasibility of engineering live biotherapeutic products (LBPs), where commensal bacteria are modified to secrete therapeutic proteins directly into human microbiomes, such as the gut (Steidler et al., Science, 2000).

This project is highly innovative because it applies the concepts of environmental bioremediation directly to the human microbiome. Instead of relying on passive physical masks or systemic drugs, it utilizes a novel application of chimeric bacterial sensors to create a “smart” biological filter. By engineering a two-component system to respond to a plant protein rather than a bacterial signaling molecule, this work challenges the assumption that mucosal defense must be entirely managed by the human immune system. This expands the boundaries of synthetic biology by proposing a programmable, symbiotic relationship between humans and engineered commensals for respiratory protection.

This project addresses the pressing real-world problem of the escalating global burden of seasonal allergies, which are worsening due to climate-change-driven increases in pollen production. The current reliance on daily antihistamines presents a significant barrier to quality of life due to side effects like fatigue and mucosal drying. If fully realized, this project could benefit society by providing a “once-a-season” localized treatment that eliminates systemic side effects entirely. Furthermore, the outcomes of this project represent a modular platform technology; if the system works for Bet v 1, the nanobody cassette can be swapped to neutralize other airborne threats, including industrial pollutants or respiratory viruses. Ultimately, this field-level change could shift allergy treatment from pharmacology to engineered preventative ecology.

Ethical Implications The primary ethical implications involved in this project center around the eventual deployment of genetically modified organisms (GMOs) into the human respiratory tract. This directly invokes the principle of non-maleficence (do no harm) and the responsibility to protect both the human host and the broader ecosystem. Introducing an engineered commensal carries the risk of unintended immune responses, potential dysbiosis of the natural nasal microbiome, or the horizontal gene transfer of the synthetic plasmid to pathogenic bacteria. Additionally, from an ecological standpoint, we must consider the risk of these engineered bacteria escaping the host via sneezing or exhalation and establishing themselves in the natural environment.

To ensure this project is conducted ethically, stringent biocontainment measures must be integrated into the fundamental design of the bacteria. I propose the implementation of a genetic “kill-switch,” specifically a strict auxotrophy for a synthetic amino acid not found in nature or the human diet. The bacteria would only survive if the user periodically applies a specialized nasal spray containing this nutrient; if discontinued, the engineered colony would rapidly die off. A potential unintended consequence of this action is genetic mutation or recombination that breaks the kill-switch, allowing the bacteria to survive independently. If we are wrong in our assumptions about the stability of the chimeric receptor, the bacteria might chronically secrete proteins, leading to localized tissue inflammation. An alternative to this live-commensal approach would be utilizing cell-free systems embedded in a physical, wearable bio-mask, which achieves the neutralization goal without the risks associated with human colonization.

SECTION 4: EXPERIMENTAL DESIGN, TECHNIQUES, TOOLS, AND TECHNOLOGY

Experimental Plan and Timeline:

Week 1 (Sequence Acquisition): Mine the Protein Data Bank (PDB) and UniProt to retrieve the exact amino acid sequences for the Bet v 1 allergen, a validated Bet v 1 nanobody (e.g., Nb16), and the standard E. coli EnvZ/OmpR two-component system.
Week 2 (Receptor Design): Utilize AlphaFold via an available high-performance computing cluster or Colab notebook to design the chimeric receptor, fusing the Nb16 nanobody to the periplasmic domain of EnvZ.
Week 3 (Structural Simulation): Run AlphaFold-Multimer to simulate the docking of the newly designed chimeric receptor with the Bet v 1 protein to verify that the binding affinity and conformational shift are preserved.
Week 4 (Plasmid Architecture): Open Benchling and construct the full genetic circuit in silico.